This study is looking at the Aveir AR Leadless Pacemaker, a small device for people with heart rhythm problems (arrhythmia) like a slow heartbeat (bradycardia). It's also comparing it to a standard single-chamber atrial transvenous pacemaker. Researchers want to understand how safe and effective the Aveir AR Leadless Pacemaker is by looking at real-world health information from Medicare beneficiaries. They will check for device-related complications within 30 days and how long people survive over two years. You might be included if you are a Medicare beneficiary who received an Aveir AR Leadless Pacemaker or a single-chamber atrial transvenous pacemaker after the study started. The study aims to include 586 people, but its current status is unclear.

Study design

This is an observational study, meaning researchers will look at existing health data rather than giving you a new treatment. It plans to include 586 Medicare beneficiaries.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Researchers will look at your health outcomes for up to two years after your pacemaker implantation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.